The cardiac action potential is primarily generated by sodium and calcium channels, which depolarize the membrane potential, and by potassium channels that repolarize the membrane potential and terminate the action potential. One of the major cardiac potassium currents is the slowly activating potassium current IKs that contribute to the action potential termination. Over 300 different inherited mutations have been found in IKs channels that cause cardiac arrhythmias in patients. IKs channels regulate the length of the cardiac contraction and mutations that decreases the activity of IKs channels result in a prolongation of the cardiac contraction, leading to Long QT Syndrome. In turn, Long QT syndrome is a risk factor for ventricular fibrillation and sudden cardiac death. We have recently identified a family of compounds that act on IKs channels and are antiarrhythmic when applied to cardiomyocytes. We will here test whether these compounds are anti- arrhythmic in human cardiomyocytes using whole-cell patch clamp and a novel pseudo-ECG in-a-dish measurements on a monolayer of human cardiomyocytes. We will also test the effect of these compounds on whole animal heart and in whole animals, in order to develop an anti-arrhythmic drug that can be tested in future clinical trial. We will also test variants of these compounds on heterologously expressed IKs channels using two-electrode voltage clamp, to determine the important structure of these compounds for their effects on IKs channels. We will also make mutations of IKS channels to determine the binding site of these compounds. Finally, we will test the efficacy of these compounds to reverse different defects in IKs channels caused by different types of Long QT syndrome mutations. This will be tested both in heterologous systems and in human cardiomyocytes. The anticipated results of these experiments will provide proof-of-concept that this family of compounds acts anti-arrhythmic and will provide preliminary animal model data to start clinical trials of these compounds. We anticipate that this development of new anti-arrhythmic drugs will lead to better treatments of cardiac arrhythmias and the prevention of sudden cardiac deaths.
Over 300 different inherited mutations have been found in IKs channels that cause cardiac arrhythmias in patients. We have recently identified a family of compounds that act on IKs channels and are antiarrhythmic when applied to cardiomyocytes. We will here test more variants of these compounds in order to develop an anti-arrhythmic drug that will lead to better treatments of cardiac arrhythmias and the prevention of sudden cardiac deaths.
|Lassuthova, Petra; Rebelo, Adriana P; Ravenscroft, Gianina et al. (2018) Mutations in ATP1A1 Cause Dominant Charcot-Marie-Tooth Type 2. Am J Hum Genet 102:505-514|
|Bohannon, Briana M; Perez, Marta E; Liin, Sara I et al. (2018) ?-6 and ?-9 polyunsaturated fatty acids with double bonds near the carboxyl head have the highest affinity and largest effects on the cardiac IKs potassium channel. Acta Physiol (Oxf) :e13186|
|Liin, Sara I; Yazdi, Samira; Ramentol, Rosamary et al. (2018) Mechanisms Underlying the Dual Effect of Polyunsaturated Fatty Acid Analogs on Kv7.1. Cell Rep 24:2908-2918|
|Larsson, Johan E; Larsson, H Peter; Liin, Sara I (2018) KCNE1 tunes the sensitivity of KV7.1 to polyunsaturated fatty acids by moving turret residues close to the binding site. Elife 7:|
|Barro-Soria, Rene; Ramentol, Rosamary; Liin, Sara I et al. (2017) KCNE1 and KCNE3 modulate KCNQ1 channels by affecting different gating transitions. Proc Natl Acad Sci U S A 114:E7367-E7376|
|Barro-Soria, Rene; Liin, Sara I; Larsson, H Peter (2017) Using fluorescence to understand ? subunit-NaV channel interactions. J Gen Physiol :|
|Barro-Soria, Rene; Liin, Sara I; Larsson, H Peter (2017) Specificity of M-channel activators: binding or effect? J Physiol 595:605-606|
|Liin, Sara I; Larsson, Johan E; Barro-Soria, Rene et al. (2016) Fatty acid analogue N-arachidonoyl taurine restores function of IKs channels with diverse long QT mutations. Elife 5:|